Our findings in MS and PTLD parallel our previous observation that anti-PAD2 antibodies are associated with milder symptoms in people with RA, and suggest that anti-PAD2 antibodies may play a role in attenuating inflammation across a spectrum of disorders. Here, PADI2 is linked to myeloid sarcoma.